Nomlabofusp clinical trials
Also written CTI-1601.
How each study uses nomlabofusp is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nomlabofusp studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Larimar Therapeutics, Inc. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nomlabofusp.
- Jan 2027An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaPhase 2 · Larimar Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses nomlabofusp is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaRecruitingPhase 2Larimar Therapeutics, Inc.NCT06447025Written as CTI-1601
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's AtaxiaRecruitingPhase 3Larimar Therapeutics, Inc.NCT07778836Written as Nomlabofusp
- A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's AtaxiaTerminatedPhase 1Larimar Therapeutics, Inc.NCT06681766Written as Nomlabofusp
- A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaCompletedPhase 2Larimar Therapeutics, Inc.NCT05579691Written as CTI-1601
- Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaCompletedPhase 1Larimar Therapeutics, Inc.NCT04519567Written as CTI-1601
- Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaCompletedPhase 1Larimar Therapeutics, Inc.NCT04176991Written as CTI-1601
Codes
What other systems call nomlabofusp · ClinicalTrials.gg INT018212
- UNII (FDA) V6S49GL5GSNOMLABOFUSPOne source FDA
- NCI Thesaurus C188641NomlabofuspOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V6S49GL5GS | NOMLABOFUSP | One source FDA |
| NCI Thesaurus | C188641 | Nomlabofusp | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.